Brandon BioCatalyst

Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, established to support the development and commercialization of early-stage biomedical discoveries. Managed by Brandon Capital, it is a unique collaboration involving major Australian superannuation funds, CSL, the Australian and New Zealand governments, state governments, and over 50 leading medical research institutes and hospitals. This partnership aims to advance the next generation of medical therapies and technologies to improve health and save lives.

The firm focuses on a wide range of sectors within the life sciences, including biotechnology, healthcare, medical devices, pharmaceuticals, diagnostics, digital health, medical research, clinical trials, regenerative medicine, immunotherapy, oncology, neurology, cardiology, endocrinology, and infectious diseases. It invests across various stages, from seed funding to pre-IPO, providing both capital and expertise to guide the successful development of new therapies. Brandon BioCatalyst has supported more than 50 companies to date, partnering with talented scientists, clinicians, and entrepreneurs to bring innovative biomedical discoveries to market.

Brandon BioCatalyst operates with a venture capital model that goes beyond providing investment; it partners with entrepreneurs to create businesses, run companies, and ensure the success of its investments. This approach includes offering non-dilutive grant funding, hands-on support, and access to global networks to new biotech spinouts emerging from academic research and small to medium-sized biotech enterprises with commercial potential. Through its initiatives, such as the CUREator program, it aims to transform promising biomedical research opportunities into clinical and market-ready solutions, benefiting patients and growing the Australian biotech ecosystem.